MAP2K7 and acute lymphoblastic leukemia: The results of these tests allow the choice of target therapies specific to each patient (e.g., quantification of BRAF V600 mutations for anti-RAF and anti-MEK target therapies, or BCR-ABL fusion genes for Imatinib treatment in chronic myeloid leukemia or lymphoblastic leukemia acute) [165].